Volume : 11, Issue : 02, February – 2024
Title:
A REVIEW ARTICLE ON THYROID CANCER
Authors :
S. Shaheena Begum , Bairipogu Divya
Abstract :
Thyroid cancer is the most frequent endocrine malignancy, with more than 500,000 cases per year worldwide. Differentiated thyroid cancers are the most common forms with best prognosis, while poorly/undifferentiated ones are rare (2% of all thyroid cancer), aggressive, frequently metastasize and have a worse prognosis. For aggressive, metastatic and advanced thyroid cancer novel antitumor molecules are urgently needed and phytochemical products can be a rational and extensive source, since secondary plant metabolites can guarantee the necessary biochemical variability for therapeutic purposes. Among bioactive molecules that present biological activity on thyroid cancer, resveratrol, curcumin, isoflavones, glucosinolates are the most common and used in experimental models. Most of them have been studied both in vitro and in vivo on this cancer, but rarely in clinical trials. This review summarizes phytochemicals, phytotherapeutics and plant derived compounds used in thyroid cancer.
The molecular abnormalities described here represent a broad effort during the past 20 years to understand the fundamental pathophysiology of thyroid cancer. Whereas early oncogenic events have been identified that probably account for the majority of these tumors, further study is needed to identify the incipient events in the remaining tumors. Just as critical is the need for a more comprehensive understanding of the steps that lead to progression, invasion, metastasis, and occasional dedifferentiation. An integrated framework will be required that merges knowledge of DNA mutations with understanding of the role of epigenetic alterations, changes in miRNA regulation of gene expression, and other fundamental processes that contribute to the malignant phenotype. Clinical trials of therapies to reverse genetic changes and alter complex signaling abnormalities will need to be informed by comprehensive, individualized tumor profiling that will facilitate the selection of the correct combination of therapies for each individual patient, including the identification of patients with sufficiently indolent tumors that no therapy will ever be required.
Cite This Article:
Please cite this article in press Bairipogu Divya et al., A Review Article On Thyroid Cancer , Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1. Wiltshire J. J., Drake T. M., Uttley L., Balasubramanian S. P. Systematic review of trends in the incidence rates of thyroid cancer. Thyroid. 2016;26(11):1541–1552. doi: 10.1089/thy.2016.0100.
2. Seib C. D., Sosa J. A. Evolving understanding of the epidemiology of thyroid cancer. Endocrinology and Metabolism Clinics of North America. 2019;48(1):23–35. doi: 10.1016/j.ecl.2018.10.002.
3. Rusinek D., Chmielik E., Krajewska J., et al. Current advances in thyroid cancer management: are we ready for the epidemic rise of diagnoses? International Journal of Molecular Sciences. 2017;18(8):p. 1817. doi: 10.3390/ijms18081817.
4. Lubitz C. C., Sosa J. A. The changing landscape of papillary thyroid cancer: AskMayoExpert. Differentiated thyroid cancer (adult). Mayo Clinic; 2018.
5. Niederhuber JE, et al., eds. Cancer of the endocrine system. In: Abeloff’s Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Jan. 21, 2022.
6. Melmed S, et al. Nontoxic diffuse goiter, nodular thyroid disorders and thyroid malignancies. In: Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Jan. 21, 2022.
7. AskMayoExpert. Medullary thyroid cancer. Mayo Clinic; 2021.
8. Thyroid carcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470. Accessed Jan. 21, 2022.
9. Vaccarella S, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. The New England Journal of Medicine. 2016; doi:10.1056/NEJMp1604412.
10. AskMayoExpert. Multiple endocrine neoplasia type 2. Mayo Clinic; 2021.
11. Suteau V, et al. Sex bias in differentiated thyroid cancer. International Journal of Molecular Sciences. 2021; doi:10.3390/ijms222312992.
12. Health Education & Content Services (Patient Education). Follow-up for low-risk thyroid cancer. Mayo Clinic; 2018.
13. Frequently asked questions about potassium iodide. U.S. Nuclear Regulatory Commission.
https://www.nrc.gov/about-nrc/emerg-preparedness/about-emerg-preparedness/potassi um-iodide/ki-faq.html. Accessed Jan. 25, 2022.
14. Wang TS, et al. Thyroidectomy. https://www.uptodate.com/contents/search. Accessed Jan. 20, 2022.
15. Thyroid cancer. Cancer.Net. https://www.cancer.net/cancer-types/thyroid-cancer. Accessed Feb. 7, 2022.
16. Health Education & Content Services (Patient Education). Thyroid surgery. Mayo Clinic; 2018.
Schumm MA, et al. Frequency of hormone replacement after lobectomy for differentiated thyroid cancer. Endocrine Practice. 2021; doi:10.1016/j.eprac.2021.01.004.epidemiology, management, and the implications for patients. Cancer. 2016;122(24):3754–3759. doi: 10.1002/cncr.30201.
17. Ito Y., Miyauchi A., Oda H., et al. Appropriateness of the revised Japanese guidelines’ risk classification for the prognosis of papillary thyroid carcinoma: a retrospective analysis of 5,845 papillary thyroid carcinoma patients. Endocrine Journal. 2019;66(2):127–134. doi: 10.1507/endocrj.ej17-0061.
18. Hajeer M., Awad H., Abdullah N., Almuhaisen G., Abudalu L. The rising trend in papillary thyroid carcinoma: true increase or over diagnosis? Saudi Medical Journal. 2018;39(2):147–153. doi: 10.15537/smj.2018.2.21211.
19. Niforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011 Aug 30;7(10):569-80.
20. miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, Dal Maso L. Thyroid cancer incidence trends by histology in 25 countries: a population- based study. Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234.
21. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol.